Video

ASCRS Live: Jim Mazzo, executive chair of Neurotech Pharmaceuticals shares company updates

Jim Mazzo, executive chairman of Neurotech Pharmaceuticals, discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Jim Mazzo, Executive Chair of Neurotech Pharmaceuticals discussed the company's goal to slow down the progression of MacTel and their recent advancements at the ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Jim Mazzo:

I am Jim Mazzo, Executive Chair out here at the ASCRS meeting, and some exciting news at Neurotech. You've probably been able to follow our journey over the years, but our journey is really moving forward very aggressively. Our whole goal is to slow down the progression of MacTel.

And I'm so pleased with what the team has been able to do through our innovative encapsulated cell therapy. We have such a unique device to be able to listen to drug to be able to slow down this terrible disease. We're moving fast. We've really accomplished a lot, but we need to do more. and we're really looking forward to working with these great retinal surgeons, rich small are CEO and the whole team have done a fantastic job. You need to pay attention to what's happening in neuro Tech because you're gonna see more and hear more from us in the future. Thanks so much for listening.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.